Objective 1

Provide updates on the latest expertise, instrumentation, and standards in enumerating Circulating Biomarkers (CBM).

Objective 2

Explore potential molecular targets on systemic cancer cells for adjuvant therapies within PM.

Objective 3

Describe the potential of CBM in cancer and neurological disorders, supported by patient data and advanced animal models.

Symposium Objectives
This symposium aims to:

The future of precision medicine (PM) is being shaped by the ability to harness Circulating Biomarkers (CBM)—a powerful class of biological indicators that provide real-time insights into disease progression, treatment response, and therapeutic targeting. From cancer to neurological disorders, CBM has the potential to revolutionise early diagnosis, risk stratification, and personalised therapy.

However, significant challenges remain in standardisation, clinical translation, and commercial adoption of CBM-based technologies. This symposium brings together leading scientists, clinicians and industry innovators to explore cutting-edge advancements and real-world applications of CBM research.

Our key objectives are

Unlocking Molecular Targets in Systemic Cancer

New Frontiers in Therapy & Drug Development

Why it matters: Circulating tumour cells (CTCs) and extracellular vesicles (EVs) offer a unique window into cancer progression and hold untapped potential for developing targeted therapies.
What we’ll cover:
  • 1. Identifying novel molecular targets on systemic cancer cells that can be leveraged for adjuvant therapies, immunotherapy, and next-gen drug delivery.
  • 2. The role of multi-omics approaches (genomics, proteomics, metabolomics, transcriptomics) in refining biomarker-driven treatment strategies.
  • 3. Industry and pharma insights: How CBM-based biomarkers accelerate companion diagnostics, biomarker-driven drug development, and commercialisation.

Personalized Monitoring & Longitudinal Tracking

The Future of Precision Medicine

Why it matters: One-time biomarker assessments offer a snapshot of disease status, but longitudinal CBM tracking provides a dynamic view of disease evolution and treatment response.
What we’ll cover:
  • 1. How real-time CBM monitoring enables early relapse detection, therapy adjustments, and disease progression tracking.
  • 2. Case studies showcasing personalized CBM-guided treatment strategies in oncology and neurology.
  • 3. The integration of liquid biopsy platforms and wearable biosensors for continuous biomarker surveillance.

Setting New Standards in CBM Analysis

Bridging Technology, AI, and Clinical Relevance

Why it matters: Accurate and reproducible CBM enumeration is essential for clinical translation, yet challenges persist in assay variability, sample handling, and standardisation.
What we’ll cover:
  • 1. The latest assays, updates, instrumentation and analytical platforms shaping CBM research's future.
  • 2. Best practices for sample collection, pre-analytical standardisation, and biomarker validation to ensure reproducibility and clinical adoption.
  • 3. How AI-driven analytics and machine learning enhance biomarker discovery, data interpretation, and predictive modelling for precision diagnostics.

CBM in Cancer & Neurology

From Biomarkers to Breakthroughs

Why it matters: While CBM has been extensively studied in oncology, its role in neurological disorders (e.g., Alzheimer’s, Parkinson’s, glioblastoma) remains underexplored.
What we’ll cover:
  • 1. The role of CBM in neuro-oncology and neurodegenerative diseases, leveraging patient-derived data and advanced animal models.
  • 2. Expanding beyond CTCs and EVs: The diagnostic potential of circulating nucleic acids (cfDNA, miRNA), tumor-educated platelets, and protein-based biomarkers.
  • 3. AI-powered pattern recognition and biomarker signature development for neurodegenerative and oncological applications.

Key Themes

Purpose

Advancing Liquid Biopsy
in Personalized Medicine

This symposium aims to enhance the understanding and application of liquid biopsy in personalised medicine for oncology and neurology.


It will update state-of-the-art methods for identifying and characterising CBM using tools like liquid biopsy, genomics, proteomics, and advanced imaging.


The event will highlight recent research and discuss CTCs, exosomes, and cfDNA for early detection, diagnosis, prognosis, and treatment monitoring of cancers and neurological disorders.

Organizers

AHERF Logo
UOD Logo

Supporting Partners

IGSTC Logo
DST (India) Logo

Knowledge Partners

Mahindra University Logo

Media Partners

Mahindra University Logo
Mahindra University Logo